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Abstract
Lung transplantation has evolved as the gold standard for selective patients 
with end-stage lung disease since the first clinical lung transplant was performed 
in 1983 in the United States. Over the last few decades, lung transplantation volume 
has increased worldwide with steadily improving outcomes; however, access to lung 
transplantation remains limited due to the critical shortage of donor organs. Factors 
that have contributed to improved outcomes include a multidisciplinary management 
approach supported by advancements in surgical and anesthetic techniques, nursing 
and critical care, immunosuppressive therapy, transplant immunobiology, and the 
perioperative use of extracorporeal membrane oxygenation (ECMO) and ex vivo 
lung perfusion (EVLP). Excellent outcomes have been achieved in selective patients 
with high-risk comorbidities such as age over 65 years, concomitant severe coronary 
artery disease (CAD), and preexisting sensitization with donor-specific antibodies 
(DSAs). Such comorbidities are no longer considered absolute contraindications 
to lung transplantation. This chapter provides an overview of perioperative care of 
lung transplant recipients with focus on a multidisciplinary approach and highlights 
management strategies for patients with concomitant severe coronary artery disease 
and end-stage lung disease as well as those with preexisting sensitization with DSAs.
Keywords: perioperative care, lung transplantation, multidisciplinary management
1. Introduction
Lung transplantation has evolved as the gold standard for select patients with end-
stage lung disease since the first clinical lung transplant was performed in 1983 in the 
United States. Over the last few decades, worldwide lung transplantation volume has 
steadily increased to approximately 4000 cases annually with progressive improve-
ments in long-term survival. Perioperative management of lung transplant recipients 
is a highly complex endeavor. Crucial components include mechanical ventilation and 
weaning strategies, fluid management, and immunosuppression including induction 
therapy, management of rejection, perioperative antibiotics, antimicrobial prophy-
laxis, chest tube management, nutritional support, discharge planning, and education.
Optimal early outcomes are dependent on a well-coordinated, multidisciplinary 
approach. Factors that have contributed to improved outcomes include advance-
ments in perioperative critical care, surgical and anesthetic techniques, improved 
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immunosuppression and understanding of transplant immunobiology, stringent post-
transplant surveillance for infection, rejection, and the perioperative use of extracor-
poreal membrane oxygenation (ECMO) [1] used to bridge decompensating patients to 
lung transplantation and ex vivo lung perfusion (EVLP) to facilitate optimization and 
transplantation of marginal donor lungs with outcomes considered equivalent to those 
from lungs transplanted using standard criteria [2, 3]. Given the aging population, 
older patients with a higher comorbid burden are being referred for lung transplant 
evaluation. In the United States, national registry data reveal a progressively increasing 
number of lung transplant recipients over age 70 years [4]. Advanced CAD is one such 
comorbidity that is no longer considered an absolute contraindication to lung trans-
plantation. Excellent early outcomes have been reported with concomitant coronary 
artery bypass grafting (CABG) and lung transplantation [5]. However, the optimal 
treatment strategy for patients with concomitant advanced CAD and end-stage lung 
disease remains controversial, requires complex decision-making, and is evolving [6].
Highly sensitized transplant candidates, i.e., those with a high titer of preexisting 
HLA donor-specific antibodies (DSA), present unique challenges requiring special-
ized perioperative management. Antibody-mediated rejection (AMR) remains a 
problem without a reliable treatment in the care of lung transplant patients. AMR is 
usually mediated by anti-HLA DSA, and both pretransplant and posttransplant DSAs 
in lung transplant recipients are associated with acute rejection, chronic allograft 
dysfunction, and decreased survival [7, 8]. Patients transplanted with pretransplant 
DSAs are at a higher risk of hyperacute/accelerated acute ABMR, chronic rejection, 
and allograft loss across all solid organs [9]. Although several desensitization protocols 
have been reported for lung transplant candidates, the guidelines for protocol selec-
tion as well as criteria for successful response to treatment remain unclear [10–12].
In this chapter, an overview of general perioperative management of the lung 
transplant recipient is presented, including specific management strategies for 
concomitant advanced CAD and end-stage lung disease and perioperative manage-
ment of the highly sensitized patient are presented.
2.  A management algorithm for concomitant severe CAD in end-stage 
lung disease
As mentioned above, the optimal treatment strategy for high-risk patients with 
advanced CAD and end-stage lung disease remains controversial, requires complex 
decision-making, and is evolving. The author [SHB] presents an algorithm for man-
agement of these high-risk patients (Figure 1). Severe CAD is defined as an angio-
graphically significant lesion (>70% stenosis) in at least one of the main coronary 
artery branches and/or when clinical or physiologic criteria demonstrate significant 
coronary flow limitation. An experienced interventional cardiologist and two 
cardiac surgeons jointly review the CAD severity of these patients upon referral for 
lung transplantation evaluation. Individualized treatment options are then formu-
lated using the presented algorithm. For example, patients who become clinically 
unstable are hospitalized and urgently evaluated and are either listed for concomi-
tant lung transplantation and CABG or CABG versus PCI, if deemed feasible, fol-
lowed by lung transplantation depending on relative disease severity. If PCI prior to 
lung transplantation is deemed necessary, coronary lesion complexity and coronary 
stent characteristics determine the duration of dual antiplatelet therapy (DAPT) 
required to prevent in-stent restenosis. In general, more complex lesions require a 
longer duration of DAPT. Recommended DAPT duration by stent type is as follows: 
(i) Bare metal stent (ideal for patients anticipated to have a short wait list time)- one 
(1) month; (ii) Synergy stent- three (3) months; and (iii) typical second generation 
3Perioperative Care for Lung Transplant Recipients: A Multidisciplinary Approach
DOI: http://dx.doi.org/10.5772/intechopen.85277
drug eluting stent- six (6) months. However, should lung transplantation become 
necessary before completion of DAPT, we proceed to lung transplantation albeit 
at a higher risk of perioperative bleeding. Close follow-up by the cardiologist and 
pulmonologist is maintained regardless of the treatment option.
3. Perioperative care of the lung transplant recipient
3.1 Intraoperative management
Preemptive management strategies that include meticulous and continuous car-
diorespiratory monitoring, prompt initiation of vasoactive pharmacotherapy, volume 
administration, and institution of extracorporeal support are of critical importance 
during specific phases of intraoperative care. During these intraoperative phases of 
care (described below), there is a high risk of hemodynamic instability, lung dere-
cruitment, worsening ventilation/perfusion mismatch, and alveolar hypoventilation 
leading to hypoxemia and hypercarbia in varying degrees of severity. The goals of 
perioperative ventilator support in lung transplantation rely on providing adequate 
minute ventilation while preventing oxygen toxicity, barotrauma, and volutrauma.
Specific problems that may occur during various intraoperative phases, and the 
recommended management strategies, are highlighted below:
3.1.1 Induction of anesthesia
Specific problems: acute RV decompensation due to (i) volume overload,  
(ii) decreased right ventricular (RV) preload and low cardiac output especially 
in the hypovolemic patient caused by increased intrathoracic pressure on 
Figure 1. 
Algorithm for management of patients with concomitant severe CAD and end-stage lung disease. LTX, lung 
transplant; PCI, percutaneous coronary intervention.
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commencement of positive pressure ventilation, (iii) Trendelenburg positioning, 
and (iv) medication-induced hypercarbia, hypoxia, and systemic hypotension 
leading to an acute exacerbation of preexisting pulmonary hypertension (PHTN) 
or severe new-onset PHTN.
Management strategies:
i. Invasive arterial blood pressure monitoring is required as hemodynamics can 
deteriorate rapidly in these patients.
ii. Temperature monitoring is mandatory as hypothermia exaggerates pulmo-
nary vascular resistance (PVR) [13]. Core temperature can be measured with 
the pulmonary artery catheter.
iii. Following induction, orotracheal intubation options for selective lung ventila-
tion include a double-lumen endotracheal tube or a single-lumen tube with a 
bronchial blocker, if a double-lumen tube cannot be passed successfully. The 
appropriate intubation strategy depends on laterality in cases of single-lung 
transplantation and surgical technique in particular whether the procedure will 
be performed using cardiopulmonary bypass (CPB) support. The intubation 
strategy should be discussed with the surgical team prior to induction.
iv. Initial ventilator parameters are adjusted according to the arterial blood 
gas (ABG) to maintain low arterial CO2 tension and prevent hypoxemia. 
Suggested parameters include tidal volume 6–7 cc/kg body weight, a posi-
tive end-expiratory pressure (PEEP) of 5 cm H2O, respiratory rate 14/min, 
inspired oxygen concentration (FiO2) to maintain arterial oxygen saturation 
above 95%, and inspiration to expiration ratio (I:E) of 1:2 to prevent auto-
PEEP especially in COPD patients.
v. Volume resuscitation is achieved with leukocyte-depleted packed red blood 
cells if the hemoglobin is <10 g/dL or colloid (albumin 5%) rather than 
crystalloid if the hemoglobin is >10 g/dL. Blood transfusion is minimized to 
due to the risk of allosensitization.
vi. Sedative agents should be administered with caution before induction as 
even minor respiratory depression may lead to increased PVR and acute RV 
decompensation.
vii. Pulmonary artery (PA) pressure monitoring via either a Swan-Ganz catheter 
or transesophageal echocardiography (TEE) is employed to guide anesthetic 
management, especially in high-risk patients.
viii. TEE monitoring is routinely performed (unless contraindicated) in all 
patients at the authors’ institution to evaluate ventricular filling, ventricular 
function, and patent foramen ovale (PFO) status and to ensure correct 
Swan-Ganz catheter tip position in the main PA to prevent inadvertent cath-
eter entrapment on clamping either branch PA. The probe is placed under 
the guidance of the attending anesthesiologist.
ix. Hemodynamic goals include avoidance of hypotension, bradycardia/tachy-
cardia and exacerbation of PHTN. Heart rate and mean arterial pressure 
(MAP) goals are 60–100/min and 70–75 mmHg, respectively. An epineph-
rine infusion (2–4 μm/min) should be prepared and started in those patients 
with a preoperative history of, or evident, pulmonary hypertension or RV 
dysfunction. Baseline physiological assessment includes an ABG, a mixed 
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venous blood gas (SvO2) from the PA port of the Swan-Ganz catheter, and 
measurement of a thermodilution cardiac output.
x. Inhaled pulmonary vasodilator therapy, e.g., inhaled nitric oxide (INO) at 
20 ppm, is used for all lung transplants at the authors’ institution and is started 
following intubation.
xi. The surgical team as well as the perfusionist should be present in the room 
during anesthetic induction and be prepared to rapidly institute resuscitative 
measures that include emergent extracorporeal life support, such as periph-
eral veno-venous ECMO, veno-arterial ECMO, or CPB.
3.1.2 Preincision
Management strategies:
i. If the decision is made to use CPB or ECMO, a 70 mg/kg IV bolus of amino-
caproic acid followed by an IV infusion at 30 mg/kg/h is given to minimize 
fibrinolysis.
ii. The induction immunotherapy protocols are detailed in Section 3.4.1 and 
Appendices (Table 1).
iii. Perioperative antibiotics: protocol details are provided in Section 3.5 below.
iv. For patients with a recent (<7 days) history of Coumadin administration, an 




i. An early trial of one-lung ventilation is advisable to see if acceptable gas 
exchange (pO2, pCO2, pH) and cardiac function can be maintained.
Protocol for all patients except CMV mismatch, HBV/HCV/HIV infection, or history of malignancy
A. Induction (intraoperative): begin induction when final decision is made by the surgeons to accept the 
lungs
1. Premedication (30 min prior to alemtuzumab)
i. Methylprednisolone (Solu-Medrol): 1 g IV
ii. Acetaminophen (Tylenol): 650 mg PO/feeding tube
iii. Diphenhydramine (Benadryl): 50 mg IV
iv. Famotidine (Pepcid): 20 mg IV
2. Alemtuzumab (Campath) 30 mg IV over 2 h
3. Methylprednisolone (Solu-Medrol): additional dose of 250 mg IV prior to reperfusion of each lung
B. Postoperative Immunosuppression (Campath):
POD#1
1. Prednisone 5 mg orally or feeding tube daily; 10 mg if on chronic prednisone therapy preoperatively
2. Standard tacrolimus and mycophenolate mofetil/MMF (Cellcept) schedule
Table 1. 
Induction therapy: Alemtuzumab (Campath).
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ii. To minimize a combustion hazard while using electrocautery:
• The FiO2 should be minimized as tolerated during lung and bronchial 
dissection.
• On isolation of the lung for explantation, the appropriate lumen of the 
double-lumen endotracheal tube is suctioned with a flexible suction 
catheter to entrain room air when the bronchus is divided.
iii. If a vasoconstrictor infusion is needed to maintain blood pressure, options 
include vasopressin 0.01–0.04 units/min (institutional preference), norepi-
nephrine 2–30 mcg/min, and phenylephrine 50–300 mcg/min, titrated to effect.
iv. Inotropic support may be provided either with IV infusions of epinephrine 
2–10 mcg/min or milrinone 0.1–0.5 mcg/kg/min (renally dosed as appropri-
ate), titrated to achieve a normal cardiac output and index.
v. Immediately prior to reperfusion of each transplanted lung, the surgeon will 
request an additional bolus of methylprednisolone 250 mg IV.
vi. In preparation for reperfusion, the hemodynamic status should be optimized 
in anticipation of volume loss to the transplanted organ and peripheral vaso-
dilation resulting from washout of vasoactive substances when the allograft 
is unclamped.
3.1.4 Postimplantation to lung allograft reperfusion/reexpansion
Specific problems: systemic vasodilatation and hypotension, reperfusion pulmo-
nary edema (increased vascular permeability and loss of lymphatic drainage), and 
hyperacute rejection.
Management strategies:
i. On completion of the vascular anastomoses, a controlled reperfusion 
maneuver is performed by gradually releasing the pulmonary artery clamp to 
prevent the development of allograft reperfusion pulmonary edema.
ii. Initial re-expansion of the donor lung is achieved with a sustained Valsalva 
maneuver to 30 cm H2O, and interruptions to ventilation should be mini-
mized thereafter.
iii. The ventilation strategy immediately posttransplant is intended to minimize 
injury to the donor lung from either mechanical factors or oxygen free radi-
cals: typical settings will be FiO2 0.40, PEEP 10 cm H2O, rate 20/min, and TV 
6 mL/kg (donor weight).
iv. Peripheral pulse oximeters are frequently inaccurate around the time of 
reperfusion, and the SvO2 may be used as an indirect measure of adequate 
oxygen exchange.
v. If oxygenation is inadequate, FiO2 may be increased in a stepwise fashion up 
to 0.60 while communicating these changes with the surgeon.
vi. If graft performance is initially inadequate, consideration should be given to 
temporarily support gas exchange with ECMO rather than use a sustained 
high FiO2.
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vii. Five minutes after reperfusion, an ABG should be checked.
viii. After reperfusion, the TEE should be used to assess for LV and RV function, 
the presence of air in the left heart, and evidence of stenosis at the pulmo-
nary vein anastomoses.
ix. A thermodilution cardiac output should be measured and recorded follow-
ing reperfusion and after chest closure.
x. A cardiac index of 2.2–2.5 is ideal—higher rates of pulmonary blood flow 
may increase the risk of significant pulmonary edema. Specific hemody-
namic optimization strategies are detailed in Section 3.1.3 above.
xi. Because of the adverse effects on donor lung function, the requirement for 
blood products should be agreed upon between the attending anesthesiolo-
gist and surgeon.
xii. The double-lumen ETT tube will need to be changed to a single-lumen ETT 
at the end of the case to facilitate flexible bronchoscopy for anastomosis 
surveillance and tracheobronchial toilet. The FiO2 should be increased 
transiently to 1.0 before this procedure.
3.1.5 Chest closure
Specific problems: restrictive chest cavity dynamics caused by:
i. Direct lung allograft compression leading to acute allograft dysfunction 
manifested by decreased compliance, derecruitment, and ventilation- 
perfusion mismatch. Etiologies include excessive donor-recipient size mis-
matching, noncompliant “frozen” pleural cavity associated with pulmonary 
fibrosis, severe pleural thickening and/or calcification, asymmetric chest 
cavities, severe kyphoscoliosis, and diaphragmatic elevation.
ii. Direct cardiac compression resulting in a cardiac tamponade physiology.
Management strategies include:
• Immediately reopening the chest
• Ventilator adjustments to prevent barotrauma, i.e., transient reductions in TV 
and/or PEEP
• Volume administration to optimize preload
• Leaving the intercostal space open with closure of only the muscular, subcuta-
neous tissue and skin layers or lung volume reduction followed by attempted 
reclosure.
3.1.6 Disruption to positive pressure ventilation
This can occur during (i) ventilator disconnection prior to patient bed to bed 
transfer, (ii) switching to a single-lumen endotracheal tube to facilitate postproce-
dure bronchoscopy, (iii) airway dislodgement, and (iv) manual ventilation while 
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the patient is being transported. Gentle Valsalva maneuvers to 30 cm H2O are 
performed immediately after any disruptions to positive pressure ventilation.
3.1.7 The use of pulmonary vasodilator therapy
The use of pulmonary vasodilator therapy with INO or epoprostenol (Flolan) is 
indicated for: (i) hypoxemia during single-lung ventilation, (ii) refractory hypox-
emia in severe primary graft dysfunction (PGD), (iii) to prevent/mitigate exacerba-
tions in PHTN and subsequent cardiorespiratory perturbations during induction and 
pulmonary artery clamping and thus potentially avoiding the institution of CPB [14].
3.2 Intensive care unit management
Initial postoperative care for all lung transplant recipients is provided on the 
intensive care unit. Interventions specific to the care of the lung transplant patient 
will include, but are not limited to, the following:
i. Ventilator management: The goal is to provide adequate minute ventilation 
while preventing oxygen toxicity, barotrauma, and volutrauma. As such, 
ventilatory parameters are individualized and adjusted to achieve these goals. 
The aim is early extubation as soon as is clinically feasible. Recommended 
ventilatory parameters are detailed in Section 3.1.4 above. In particular, the 
goal is the use the lowest FiO2 to maintain arterial oxygen saturations greater 
than 91% and a tidal volume based on donor height (where possible) to 
prevent/minimize PGD [15, 16].
ii. INO weaning protocol: In single-lung transplants for pulmonary fibrosis, 
the author [SB] recommends weaning INO first (if used) within the first 
6–12 h followed by oxygen and PEEP weaning, as tolerated. In single-lung 
transplants for COPD, the PEEP is weaned first (to prevent compression of 
the less compliant lung allograft by the hyperinflated native lung) followed 
by INO (within 6–12 h) and oxygen weaning, as tolerated. After double-lung 
transplants, the goal is to wean INO within 24 h. Following extubation, the 
patient will be instructed in the use of the incentive spirometer and the flut-
ter valve. Early mobilization out of bed to chair is instituted.
iii. Hemodynamic management and fluid administration protocol: Due to the 
propensity of lung allografts to develop pulmonary edema (altered tis-
sue hydrostatic forces, endothelial dysfunction, destruction of lymphatic 
drainage channels), the goals are to maintain adequate cardiac output; avoid 
high cardiac output states; wean inotropes rapidly when no longer clini-
cally indicated; use colloid (albumin 5%) rather than crystalloid for volume 
replacement; medication infusions are concentrated to reduce volume 
loading; maintain hemoglobin at 10 g/dL with leukocyte-depleted packed 
red blood cells, CVP 10–12 mmHg, and MAP 65–75 mmHg; and adjust 
appropriately for urine output above 0.5 mL/kg body weight, SvO2 > 65%, 
and lactate <2 mmol/L. Additional blood products are given per clinical need 
(FFP, cryoprecipitate, and platelets).
• A cardiac index of 2.2–2.5 is ideal—to minimize the risk of significant pul-
monary edema. Specific hemodynamic optimization strategies are detailed 
in Section 3.1.3 above. Serial lactate levels and SvO2 are measured every 6 h 
or as needed depending on clinical status.
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• Once clinically stable and not on high-dose pressors, aggressive diuresis as 
dictated by the patient’s clinical status and radiographic findings is initi-
ated with Lasix 20–40 mg IV every 8 h or a Lasix infusion 0.5–4 mg/min, 
titrated to achieve a negative intake/output balance (500 mL to 1 L) over 
the initial 24 h.
iv. Postoperative pain and sedation management: Important goals include use 
of the lowest effective dose and timely weaning of opioids such as fentanyl 
infusion 0.5–1.5 mcg/kg/h or 50–100 mcg IV boluses every 1–2 h (use renal 
dosing where applicable), sedatives such as Precedex 0.2–1.4 mcg/kg/h, and 
anxiolytics such as Versed 0.02–0.1 mg/kg/h to prevent respiratory depres-
sion, hypotension, oversedation, and delayed extubation.
v. Flexible bronchoscopy is performed on all patients prior to extubation to facili-
tate tracheobronchial toilet and to evaluate the integrity of the airways.
vi. Chest tube removal is started in POD#1 once criteria are met (no air leak, 
total serosanguineous drainage <200 mL/24 h, and/or <20 mL/h for the three 
consecutive hours prior to planned removal). Our institutional protocol 
involves removal of the posterior-dependent chest tube first, conversion of 
the anterior and middle chest tubes to H2O seal, and removal of the ante-
rior and last the middle chest tube when the patient has been ambulant to 
minimize residual pleural effusion collections.
vii. Nutritional support: While oral intake of all medications and nutrition is 
preferred, the patient will undergo a swallowing assessment 24–48 h fol-
lowing extubation and a nutritional assessment within 48 h after admission 
to the ICU. Until oral intake is established, for patients deemed at high risk 
of aspiration, a postpyloric naso-enteric feeding tube is placed immediately 
on extubation. In low-risk patients, orogastric tube feeds are started shortly 
after arrival to the ICU absent contraindications that include known severe 
gastroesophageal reflux disease, gastric distension, esophageal dysmotility 
syndromes, and high pressor requirements. The dietitian will make individu-
alized recommendations for the patient’s nutritional needs and will follow 
the patient throughout the hospitalization and make recommendations to 
the team accordingly. Gastroenterology consultation will be initiated as war-
ranted by the patient’s condition.
viii. DVT prophylaxis will be initiated per hospital protocol (subcutaneous hepa-
rin 5000 units every 8 h). Weekly surveillance upper and lower extremity 
Doppler studies are performed.
ix. Physical therapy consultation will be completed within 48 h of transplanta-
tion; early mobility is the goal.
3.2.1 Primary graft dysfunction
PGD is an acute manifestation of ischemia-reperfusion injury associated with 
multiple risk factors (donor-derived and related to procurement/preservation and 
reperfusion) with a peak incidence within the first 72 h after lung transplanta-
tion [17, 18]. The severity of PGD is graded based on the presence or absence of 
diffuse opacities on chest radiograph and the ratio of arterial oxygen pressure to 
inspired oxygen concentration, i.e., the PaO2/FiO2 ratio. The severity ranges from 
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grade 0 (absent radiographic infiltrates, any PaO2/FiO2 ratio, extubated patient 
with/without supplemental oxygen) to grade 3 (radiographic infiltrates present 
bilaterally or, if single-lung transplant—absent in the native lung, PaO2/FiO2 ratio 
<200, mechanical ventilation with FiO2 >50% for 48 h, requirement for extra-
corporeal life support). Severe PGD negatively impacts short-term outcome after 
lung transplantation (30-day mortality up to 50%) and is also associated with 
the development of chronic allograft dysfunction, i.e., bronchiolitis obliterans 
syndrome [15, 19, 20]. Management of PGD is predominantly supportive, i.e., 
cardiorespiratory support including lung protective ventilation, inhaled pulmo-
nary vasodilator therapy, fluid and transfusion restriction, diuretic therapy, and 
extracorporeal life support for refractory hypoxemia with/without hemodynamic 
instability [21, 22].
3.2.2 The role of extracorporeal support: ECMO versus CPB in lung transplantation
In the United States, the rate of CPB use during lung transplantation varies 
widely. CPB provides hemodynamic stability with the heart in a decompressed 
state, which affords technical advantages by reducing right heart distension and 
vascular wall tension/shear stress, especially in the presence of moderate pulmo-
nary hypertension. This facilitates nontraumatic vascular clamping and the perfor-
mance of tension-free anastomoses. However, several studies have reported worse 
early postoperative outcomes as compared to off-pump lung transplantation [23, 
24]. ECMO as an alternative to CPB provides certain advantages: reduced heparin 
requirements, reduced systemic inflammatory response, and coagulopathy result-
ing in less bleeding and lower transfusion requirements. Additionally, ECMO can be 
continued into the early postoperative period to facilitate allograft recovery while 
optimizing cardiorespiratory support.
3.3 Immunologic assessment of the lung transplant recipient
To decrease the immunologic AMR risk posttransplant, high-titer pretrans-
plant DSAs that result in positive complement-dependent cytotoxicity (CDC) 
crossmatch and cause hyperacute rejection should be effectively avoided or 
preemptively treated based on acceptable risk defined by the transplant center. 
However, antibody avoidance results in longer waiting times and death on wait-
ing list. At TUH, about 13% of waitlisted patients have CPRA > 80% (11 out of 83 
active patients), but only about 3.5% of transplanted patients have CPRA > 80% 
(12 out of 345 patients transplanted between 2016 and 2017), showing a dispar-
ity in transplantation rates for highly sensitized patients (Figure 2). In thoracic 
transplantation, the use of the virtual crossmatch without a prospective serologic 
crossmatch became the standard practice. In virtual crossmatch, compatibility 
between donor and recipient is predicted by comparing the recipient’s HLA-
specific antibodies with the HLA antigens of the prospective donor. The primary 
method for antibody identification is the solid-phase single-antigen bead (SAB) 
assay that provides information about antibody specificities and their relative 
strengths based on mean fluorescence intensity (MFI) readout. Figure 3 shows 
examples of positive and negative virtual crossmatches performed using SAB 
results that allow evaluation of compatibility between the donor and the recipient. 
However, there are several limitations to accurate virtual crossmatching based on 
SAB assay alone, including (1) that SAB assay is prone to detection of the so-called 
naturally occurring antibodies against denatured/cryptic antigens and that (2) it is 
not clearly understood at what MFI threshold DSA should be considered as clini-
cally relevant [25].
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The precise role of naturally occurring antibodies is not well understood yet, but 
several studies suggest that such antibodies do not have clinical significance [26–29]. 
Usually antibodies against cryptic epitope do not result in positive flow cytometric 
or CDC crossmatches and do not impact clinical posttransplant outcomes. Several 
reports demonstrated that some antibodies detected in SAB assays may be directed 
against cryptic epitopes on recombinant HLA proteins created by missing pep-
tides and/or b2-macroglobulin [30]. Other studies estimate that about 20–30% of 
waitlisted patients have antibodies against denatured antigens [28]. The naturally 
occurring antibodies can easily be recognized by negative reactions in cell-based 
crossmatch testing, but thoracic programs rarely have a luxury of performing a 
prospective crossmatch. Therefore, when/if not recognized as antibodies against 
denatured antigens, these specificities can deny an organ transplant based on virtual 
crossmatch. Starting in October 2016, our center began modifying our existing 
HLA testing protocols to better identify patients with and without pretransplant 
DSA by using multiple assay platforms, including FlowPRA Screen, phenotypic 
beads, and the well-established single-antigen beads. We studied 58 consecutive 
Figure 3. 
Examples of negative (A) and positive (B) virtual crossmatches using results of single-antigen bead assay.
Figure 2. 
Only 4% of transplanted patients (12/296) have CPRA > 80%, while 13% (11/83) patients on the 
waitlist have CPRA >80%.
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VXM performed during July–December 2016 for lung candidates with CPRA>10%. 
Twenty-eight patients had no DSAs or had acceptably weak DSAs; they proceeded to 
transplant based VXM. All retrospective flow crossmatches were negative. The other 
30 patients had positive VXM due to one or more moderate to strong DSAs, and the 
organ offers were refused. We found that 7 out of 30 (23.3%) VXM were called unac-
ceptably positive due to the presence of antibody against denatured antigens [31]. 
Among these seven patients, three patients had antibodies against class I denatured 
antigens (2500–3500 MFI), and four patients had antibodies against class II dena-
tured antigens (2000–14,000 MFI). We also found that by using LSPRA (Phenotypic 
Bead) and FlowPRA Screen assays along with SAB, we can preemptively recognize 
antibodies against denatured antigens not to deny organ offers unnecessarily. Instead 
of performing VXM using only SAB results, we now confirm that donor’s antigens 
are positive by other assays as well (Figure 3A). Whenever antibody is detected only 
by SAB assay, it is considered to be directed against a cryptic epitope and, therefore, 
to be clinically irrelevant and not able to cause positive flow cytometry crossmatch 
(Figure 4A). DSAs detected by both SAB and phenotypic bead assays are considered 
as antibody against native HLA antigens (Figure 4B). The “true” DSAs undergo 
evaluation for strength as described below. Using this strategy we successfully 
transplanted five out of seven patients who were denied offers during July–December 
2016 period. Since January 2017, all transplant candidates undergo antibody testing 
by SAB and LSPRA/FlowPRA Screen assays, so the presence of antibodies against 
cryptic epitopes can be easily recognized at the time of donor evaluation. This strat-
egy results in reducing the number of unacceptable antigens and reduces percentage 
Figure 4. 
Accuracy of virtual crossmatch can be improved by performing SAB alone with screening assays.
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of CPRA (the percent of incompatible donors). Our data on relevance of antibodies 
against cryptic epitopes correlate well with several recent studies, including meta-
analysis of 13 cohorts of lung recipients (total 3039 patients) showed that only DSAs 
that were detected by both SAB and screening assays were associated with CLAD 
(HR = 2.02, 95% CI = 1.37–2.97, P < 0.001). When DSAs were detected by SAB alone, 
the association with CLAD was no longer significant [32]. Overall, our experience is 
that use of SAB assay by itself may unnecessarily deny an organ offer due to the false-
positive reactions and that use of screening assays improves the accuracy of virtual 
crossmatches and provides additional opportunities for sensitized patients.
Another important consideration is how to determine a threshold level below which 
DSA is clinically irrelevant or manageable perioperatively. Mean fluorescence intensity 
units somewhat indicate the quantity of antibody binding, when serum is pretreated 
with EDTA to inactivate complement and remove prozone-like inhibition in SAB assay. 
It is important to note that when untreated serum is used, the correlation between MFI 
and antibody quantity is very poor [33]. MFI values cannot be reliably measured above 
20,000 MFI due to saturation effect, and intercenter studies suggest that the positive 
cutoff for DSA should be ~1500 MFI [33]. At TUH, antibodies <3000 are considered 
as weak and can be crossed without perioperative treatment, while antibodies >10,000 
strong in general considered as strong and present unacceptably high risk. For patients 
with CPRA < 50%, UA are listed in UNET based on 3000 MFI cutoff. However, for 
patients with CPRA >50%, the immunologic management strategy differs depending 
on the urgency for transplant and the strength of antibody specificities.
Data from our center show that it is possible to reduce HLA antibody levels 
temporarily using various protocols, including high dose of IVIG plus Rituxan or 
five plasma exchanges with or without bortezomib (Velcade) followed by high dose 
of IVIG. However, if not transplanted during that “window of opportunity,” the 
patient’s antibodies invariably rebound and sometimes to the levels even higher than 
prior to initiation of desensitization. Even for patients with high LAS, who receive 
a priority during allocation, it is not easy to predict when a “compatible” donor may 
become available. Instead of implementing desensitization while patients are waiting 
for the offers, the Toronto Lung Transplant Program has developed a perioperative 
desensitization protocol-guiding organ allocation and maintenance immunotherapy 
[34]. At TUH, Toronto’s protocol is implemented with some modifications. Highly 
sensitized patients with antibodies >3000 MFI are additionally tested at 1:16 serum 
dilution. Antibodies that become <3000 MFI at 1:16 are usually not listed as unaccept-
able antigens (UA) in UNET, while antibodies >3000 MFI at 1:16 are generally listed 
as UA. Our center experience is that antibodies <3000 MFI would result in borderline 
or low-positive flow cytometry crossmatch and can be managed postoperatively as 
needed. Therefore, if antibody decreases to <3000 at 1:16 dilution, it will result only at 
most in low-positive flow crossmatch after a single plasma exchange. This additional 
step allows us to avoid a prospective crossmatch for rapidly declining patients with 
high CPRA and to accept an offer based on VXM. The treatment usually continues 
posttransplant with additional 4–5 plasma-exchange sessions, followed by high dose 
of IVIG and Rituxan as needed. The perioperative desensitization is implemented at 
the time of transplant decision-making, which reduces unnecessary treatments and 
the risk of complications for patients who did not proceed to transplant.
3.4 Immunosuppressive therapy
3.4.1 Induction therapy
Induction therapy is determined at the time of listing and is modified for the patient 
as medically indicated. Induction therapy is administered in the operating room by the 
Perioperative Care for Organ Transplant Recipient
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anesthesiologist. Exceptions to the standard therapy are documented in the patient’s 
medical record. Alemtuzumab (Campath) is the first-line induction therapy (Table 1). 
Basiliximab (Simulect) is given to patients with cytomegalovirus (CMV) mismatch, 
Hepatitis B virus (HBV)/HCV/HIV infection, and/or a history of malignancy (Table 2).
3.4.2 Postoperative immunosuppression
i. Postoperative immunosuppression is a combination therapy including a 
calcineurin-inhibitor therapy (CIT), steroids, and antimetabolite therapy. 
The postoperative immunosuppression administration and dosing guidelines 
are found in Tables 1–3.
ii. Tacrolimus is the first-line CIT and is initiated on the first postoperative day 
(POD) #1 via the sublingual route of administration. Initiation of tacrolimus 
may be held at the discretion of the lung transplant surgeon and/or trans-
plant pulmonologist if the patient is not hemodynamically stable, aggressive 
diuresis is required, or there is evidence of renal complications. Oral medica-
tion will be administered when the patient has been cleared for oral intake. 
The intravenous route of administration is not preferred.
iii. Postoperative steroid therapy begins on POD #1 and the dosing is based on 
the specified induction therapy for the patient.
iv. Mycophenolate mofetil (Cellcept) is the first-line antimetabolite and begins 
on POD #1 if the platelet count is greater than 40,000 and rising and the 
lymphocyte count is greater than 10. The dose is reevaluated daily for titra-
tion to goal of 750 mg Q12 h.
v. For patients receiving basiliximab (Simulect) based induction, an additional 
dose of basiliximab (Simulect) is administered on POD #4.
Protocol for patients with CMV mismatch HBV/HCV/HIV infection, or history of malignancy
A. Induction (intraoperative): begin induction when final decision is made by the surgeons to accept the lungs
1. Basiliximab (Simulect) 20 mg IV and methylprednisolone (Solu-Medrol) 1 g IV at the start of the 
procedure
2. Methylprednisolone (Solu-Medrol): additional dose of 250 mg IV prior to reperfusion of each lung
B. Postoperative immunosuppression (Simulect)
1. POD #1 Steroid taper
Begin with methylprednisolone (Solu-Medrol) IV and switch to prednisone when tolerating PO
POD Prednisone (mg) Methylprednisolone (mg)
1 50 daily 20 Q 12 h
2 40 daily 32 daily
3 30 daily 24 daily
4–14 20 daily 16 daily
15 15 daily 12 daily Taper dose to 0.1 mg/kg/
day by 3 months
2. Standard tacrolimus (Prograf) and MMF (Cellcept) schedule
POD #4 Basiliximab (Simulect) 20 mg IV
Table 2. 
Induction therapy: Basiliximab (Simulect).
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3.4.3 Maintenance and monitoring of immunosuppressant levels
Daily tacrolimus level measurements are taken. The target tacrolimus level is 
10–15 ng/dl with a goal level of 12. In general, once the tacrolimus level is within 
this range, trough levels will be measured every Monday, Wednesday, and Friday 
or prior to the administration of the fourth dose. The target level is maintained 
throughout the first six (6) months posttransplantation.
Tacrolimus may be switched to cyclosporine if clinically warranted. 
Cyclosporine is maintained at a target level of 350–400 ng/ml. When the patient is 
able to take medications orally, the parenteral cyclosporine medication is changed 
to Neoral given every 12 h. The target level is maintained throughout the first 
6 months posttransplantation. Cyclosporine trough levels are monitored in the same 
manner as described above for tacrolimus levels.
In the immediate postoperative period, daily monitoring of complete blood 
count, platelet count, liver function data, electrolytes, magnesium, calcium, phos-
phorus, and creatinine is performed. Frequency of blood draws is modified based 
on the patient’s clinical condition. A baseline immune cell function level is obtained 
preoperatively, 1 week postoperatively, and prior to lung biopsies.
3.5 Perioperative antibiotic therapy
3.5.1 Intraoperative phase
Antibiotics are given in the operating room 1 h or less before incision and include 
vancomycin l g IV and cefepime 2 g IV (if allergic to penicillin, substitute cipro-
floxacin 400 mg IV). Metronidazole (Flagyl) 500 mg IV is used only for patients 
with a history of prior Clostridium difficile infection.
3.5.2 Immediate postoperative phase
Postoperatively, the patient is given vancomycin 15 mg/kg IV every 12 h for 
3 days (patients with a creatinine clearance of less than 50 will require renal dosing 
of vancomycin) and cefepime 2 g IV every 12 h for 3 days to begin 12 h after the 
dose given in the operating room. Ciprofloxacin 400 mg IV every 8 h for 3 days is 
substituted for patients with a penicillin allergy. Metronidazole (Flagyl) 500 mg 
IV is used only for patients with history of prior Clostridium difficile infection. 
Antibiotic therapy is adjusted by the team based on donor culture/gram stains and 
allergy history.
The Transplant Infectious Disease physician is consulted on all postoperative 
transplant patients.
POD#1
1. Tacrolimus (Prograf) 0.5 mg orally or sublingual Q 12 h (target 10–12): IV route is to be avoided. Begin 
when patient is hemodynamically stable and aggressive diuresis is not required. For split doses, the higher 
dose is scheduled for the evening
2. MMF (Cellcept) 250 mg orally or feeding tube Q 12 h: dose if lymphocyte count greater than or equal to 10 
and/or platelet count greater than or equal to 40 K (oral dose = IV dose). Reevaluate daily for titration to goal 
of 750 mg Q 12 h
Prograf dose on the day of discharge from initial transplant admission is required to be greater than or 
equal to 6
Table 3. 
Postoperative immunosuppression: all patients.




Patients are ordered antifungal prophylaxis on admission to the 
ICU. Voriconazole (Vfend) is the first-line agent. Amphotericin B lipid complex 
(Abelcet) will be ordered for patients with intolerance to voriconazole (Vfend).
3.6.2 PCP prophylaxis
The patient is ordered Bactrim DS one (I) tab Monday, Wednesday, and Friday 
when the patient is discharged following transplant. Atovaquone (Mepron) 750 mg 
every 12 h is substituted or monthly inhaled pentamidine for patients with a sulfa 
allergy. PCP prophylaxis is given throughout the patient’s posttransplant course.
3.6.3 CMV prophylaxis
Cytomegalovirus (CMV) prophylaxis is initiated on the POD# 1 based on the 
donor and recipient CMV status. CMV infection following the completion of 
the prophylaxis is treated at the induction dose for 3 weeks then decreased to the 
maintenance dose. Duration of therapy is determined in consultation with the 
Transplant Infectious Disease physician.
4. Conclusions
Lung transplantation has evolved as the gold standard for selective patients 
with end-stage lung disease but remains limited by a critical donor shortage. 
Perioperative management of lung transplant recipients is a highly complex 
endeavor. National registry data reveal progressively improving early as well as 
long-term survival. Optimal perioperative outcomes are dependent on preemptive, 
well-coordinated, and multidisciplinary management strategies. Certain high-risk 
patient subsets with end-stage lung disease such as highly sensitized patients, and 
those with concomitant severe CAD present unique challenges requiring specialized 
perioperative management.
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